Press release
Gossamer Bio Appoints Bob Smith as Chief Commercial Officer
- Mr. Smith is a recognized leader in the commercialization of PAH products, most recently leading sotatercept US pre-launch activities at Merck - -
About this update from Gossamer Bio, Inc.
[{"type":"text","content":"\n- Mr. Smith is a recognized leader in the commercialization of PAH products, most recently leading sotatercept US pre-launch activities at Merck -\n\n\n- Previously, Mr. Smith led US sales operations for Actelion -\n\n\n SAN DIEGO--(BUSINESS WIRE)--\nGossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH), today announced the appointment of Bob Smith as its Chief Commercial Officer.\n\n\n“We are proud to welcome Bob Smith to the Gossamer team and his 30 years of expertise at this critical time in our company’s history,” said Faheem Hasnain, Chairman, Co-Founder and CEO of Gossamer Bio.\n\n\n“With Bob’s arrival, Gossamer is well-positioned to transition itself from a pre-commercial, clinical-stage biotechnology company to a fully integrated commercial organization focused on bringing seralutinib to patients with pulmonary hypertension. Given his distinguished experience as a senior commercial leader at both Merck and Actelion, and having launched significant PAH brands, we are confident that Bob is the best person for this key role, and we appreciate the confidence that such an accomplished commercial professional has shown in seralutinib by joining Gossamer Bio.”\n\n\n“I am excited to join the Gossamer Bio team at this pivotal time and to contribute to its mission to enhance the lives of patients living with pulmonary hypertension,” said Mr. Smith. “I believe that seralutinib has the potential to be a treatment paradigm-altering therapeutic in PAH. The mechanism of action, convenience, safety profile seen to date, and the possibility of reverse remodeling are all potential differentiators in a life-threatening disease with high unmet need. I look forward to getting this important and needed treatment to patients.”\n\n\nMr. Smith has over 30 years of experience in pharmaceuticals, with a strong focus on PAH and rare disease. Since January 2023, Mr. Smith has been the National Sales Lead in charge of preparing for the potential launch of sotatercept for the treatment of PAH in the US at Merck & Co. Prior to this, Mr. Smith was the President of LTM Pharma Consulting, where he helped build strategic brand, launch and organization plans for pre-commercial rare disease companies.\n\n\nPrevi...